Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer Journal Article

Authors: Qiu, W. G.; Polotskaia, A.; Xiao, G.; Di, L.; Zhao, Y.; Hu, W.; Philip, J.; Hendrickson, R. C.; Bargonetti, J.
Article Title: Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
Abstract: Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53 we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose polymerase has a positive association with mutant p53 on the chromatin. Here, for the first time we report that the heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant p53-chromatin associated pathway. Enrichment analysis identified the minichromosome maintenance members 2-7. To validate this mutant p53-poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin. Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4. To target the mutant p53-poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2-7 activity was inhibited the synergistic activation of apoptosis was blocked. This mutant p53-poly ADP-ribose polymerase -minichromosome maintenance axis may be useful for theranostics.
Keywords: down-regulation; in-vivo; p53; li-fraumeni-syndrome; cells; inhibitors; dna-damage; tumor-antigen; parp; gain-of-function; genomic landscape
Journal Title: npj Breast Cancer
Volume: 3
ISSN: 2374-4677
Publisher: Nature Publishing Group  
Date Published: 2017-01-19
Start Page: 1
Language: English
ACCESSION: WOS:000411079800001
DOI: 10.1038/s41523-016-0001-7
PMCID: PMC5319483
PUBMED: 28232952
Notes: Article -- Source: Wos
Altmetric Score
MSK Authors
  1. John Philip
    20 Philip